,~w-fO q# g oG#wGGG T1@c*Z=1`cd (J!Zf H ~5N8p `#`Od%jsm 40,s@;sPP,P@ |5O^ NR\+tN,NR DG o:iHV5iw i=Lc J~oPBf~3BJ~@JPmYFJJ k:m:G ,,]woj, ?J\LArSJhKS 8qGmqBxn uS::3. mg| 2TBoq+B eY bXV 4;8 Xp?FY zFz-,*r* VW ^GC( #icHq H%L 1{`e`$2`% (U wpW? $YWcJ:!!c.

Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL. This PFS benefit was reported across all major subgroups, including the del(17p)/t,yN^L@# population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac safety profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.